References
- Boivin J, Bunting L, Collins JA, et al. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007;22:1506–1512.
- Boivin J, Domar AD, Shapiro DB, et al. Tackling burden in ART: an integrated approach for medical staff. Hum Reprod. 2012;27:941–950.
- Brandes M, Van Der Steen JO, Bokdam SB, et al. When and why do subfertile couples discontinue their fertility care? A longitudinal cohort study in a secondary care subfertility population. Hum Reprod. 2009;24:3127–3135.
- Pasch LA, Holley SR, Bleil ME, et al. Addressing the needs of fertility treatment patients and their partners: are they informed of and do they receive mental health services? Fertil Steril. 2016;106:209-215.e2. Epub 2016/03/29.
- Schaller MA, Griesinger G, Banz-Jansen C. Women show a higher level of anxiety during IVF treatment than men and hold different concerns: a cohort study. Arch Gynecol Obstet. 2016;293:1137–1145.
- Moura-Ramos M, Gameiro S, Canavarro MC, et al. Does infertility history affect the emotional adjustment of couples undergoing assisted reproduction? The mediating role of the importance of parenthood. Br J Health Psychol. 2016;21:302–317.
- Olivius C, Friden B, Borg G, et al. Why do couples discontinue in vitro fertilization treatment? A cohort study. Fertil Steril. 2004;81:258–261.
- Buhler K. Managing infertility with the follitropin alfa prefilled pen injector - patient considerations. Ther Clin Risk Manag. 2015;11:995–1001.
- Christen M, Schertz JC, Arriagada P, et al. The redesigned follitropin alpha pen injector for infertility treatment. Expert Opin Drug Deliv. 2011;8:833–839.
- Merck Sharp and Dohme B.V. FOLLISTIM® AQ Cartridge (follitropin beta injection) for subcutaneous use 2014. [ cited 2016 Sep 16]. Available from: http://www.merck.com/product/usa/pi_circulars/f/follistim_aq_cartridge/follistim_cartridge_pi.pdf
- Finox Biotech AG. Bemfola 150 IU/0.25 ml solution for injection in a pre-filled pen 2016. [ cited 2016 Sep 16]. Available from: https://www.medicines.org.uk/emc/medicine/30402
- Schertz JC, Saunders H, Hecker C, et al. The redesigned follitropin alfa pen injector: results of the patient and nurse human factors usability testing. Expert Opin Drug Deliv. 2011;8(9):1111–1120.
- Mahony MC, Patterson P, Hayward B, et al. Human factors engineering and design validation for the redesigned follitropin alfa pen injection device. Expert Opin Drug Deliv. 2015;12(5):715–725.
- Abbotts C, Salgado-Braga C, Audibert-Gros C. A redesigned follitropin alfa pen injector for infertility: results of a market research study. Patient Prefer Adherence. 2011;5:315–331.
- Administration. USFaD. Guidance for Industry and Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Medical Devices. [ update 3 Feb 2016; cited 19 Oct 2016]. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm259760.pdf
- Jeannerot F, Studeli T, Gunther-LaVergne L, et al. Usability engineering study in the European Union of a redesigned follitropin alfa pen injector for infertility treatment. Expert Opin Drug Deliv. 2016;13:1221–1229.
- Jeannerot F, Cusin A, Schertz J. Dose accuracy of the redesigned follitropin alfa pen injector for infertility treatment. Expert Opin Drug Deliv. 2016; 13:1661–1669.
- Merck. News release: Merck set to launch new version of fertility pens 2016. [ cited 2016 June 13]. Available from: http://news.merck.de/N/0/EE522B31052D6766C1257F4C0038A469/$File/Pen_2.0_EN.pdf
- Red Dot Award. Red dot award: product design 2015. [ cited 2016 May 24]. Available from: http://red-dot.de/pd/online-exhibition/work/?lang=en&code=26-02047-2015&y=2015&c=167&a=0